Logotype for Dimed S.A. Distribuidora de Medicamentos

Dimed (PNVL3) Q2 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Dimed S.A. Distribuidora de Medicamentos

Q2 2026 earnings summary

7 Aug, 2026

Executive summary

  • Achieved consolidated gross revenue of R$1.635 billion in 2Q26, up 15.7% year-over-year, with retail revenue growing 15.8%.

  • Adjusted EBITDA reached R$88.5 million (5.4% margin), up 26.4% year-over-year, and adjusted net income was R$38.9 million (2.4% margin), up 39.1%.

  • Digital sales represented 33.7% of retail gross revenue, with app sales up 155.9% and digital penetration up 9.3 p.p. year-over-year.

  • Same-store sales grew 13.5% and mature store sales 11.4%, both above inflation.

  • Maintained low leverage with net debt/EBITDA at 0.91x and positive free cash flow for the sixth consecutive quarter.

Financial highlights

  • Consolidated gross profit was R$493.9 million in 2Q26, up 13.9% year-over-year, with a gross margin of 30.2%.

  • Adjusted EBITDA margin expanded by 0.4 p.p. to 5.4%, and adjusted net margin also grew by 0.4 p.p. to 2.4%.

  • Free cash flow was positive at R$1.9 million, marking the sixth consecutive quarter of positive cash generation.

  • Net debt/EBITDA ratio improved to 0.91x from 1.1x a year earlier.

  • Investments totaled R$35 million in 2Q26, focused on store openings, IT, and logistics.

Outlook and guidance

  • Management reaffirmed confidence in the 2030 strategic plan, highlighting strong fundamentals and continued digital acceleration.

  • Expectation of increased investments in store openings and refurbishments in the second half of 2026.

  • Continued focus on digital expansion, store productivity, and margin improvement.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more